Serum soluble toll-like receptor 2 and 4 as diagnostic and prognostic biomarkers for non-Hodgkin lymphoma

Nouran Fakhry; Ahmed Gowily; Tarek Okda; Maha Houssen

doi:10.5114/wo.2020.100270

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2020
vol. 24

Send email

Copy url:

abstract:

Original paper

Serum soluble toll-like receptor 2 and 4 as diagnostic and prognostic biomarkers for non-Hodgkin lymphoma

Nouran Fakhry

¹

,

Ahmed Gowily

²

,

Tarek Okda

¹

,

Maha Houssen

¹

Department of Biochemistry, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
Department of Clinical Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Contemp Oncol (Pozn) 2020; 24 (3): 157–162

DOI: https://doi.org/10.5114/wo.2020.100270

Online publish date: 2020/10/30

View full text Get citation

PlumX metrics:

Introduction
To assess the serum levels of soluble toll-like receptor 2 (sTLR2) and soluble toll-like receptor 4 (sTLR4) in a group of patients with non-Hodgkin lymphoma (NHL) and to investigate their correlations with the clinicopathological parameters of NHL.

Material and methods
Fifty patients with early-stage NHL and 50 patients with advanced-stage NHL along with 50 age- and sex-matched healthy volunteers were enrolled in the study. Serum levels of sTLR2 and sTLR4 were measured using enzyme-linked immunosorbent assay (ELISA).

Results
A significant increase in the serum levels of sTLR2 (pg/ml) was detected in early stage NHL (group I) (2381.1 ±1822.0) and advanced stage NHL (group II) (2864.9 ±2599.9) when compared to levels in the control group (1229.2 ±70.55) (p < 0.001). A significant increase in the serum levels of sTLR4 (pg/ml) was detected in early stage NHL (2465.4 ±3501.8) and advanced stage NHL (4759.7 ±5176.2) when compared to levels in the control group (1242.3 ±53) (p < 0.001). A significant positive correlation was detected between the serum levels of both sTLR2 and sSTLR4 and the Ann Arbor staging of NHL.

Conclusions
sTLR2 and sTLR4 might be diagnostic and prognostic biomarkers for NHL.

keywords:

Serum soluble toll-like receptor 2 and 4 as diagnostic and prognostic biomarkers for non-Hodgkin lymphoma

Nouran Fakhry 1 , Ahmed Gowily 2 , Tarek Okda 1 , Maha Houssen 1

TLR, sTLR2, sTLR4, NHL, ELISA

Nouran Fakhry

¹

,

Ahmed Gowily

²

,

Tarek Okda

¹

,

Maha Houssen

¹